Neurotoxins and drugs for the treatment of Parkinson's disease. Part I: Neurotoxins, levodopa, and agents influencing dopamine metabolism (a review)

Pharmaceutical Chemistry Journal

Volumn 39, Issue 9, 2005, Pages 453-465

  Kadieva, M G ^a   Oganesyan, E T ^b   Mutsueva, S Kh ^b  

^a NORTH OSSETIAN STATE UNIVERSITY   (Russian Federation)

^b VOLGOGRAD STATE MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

1 BENZYL 1,2,3,4 TETRAHYDROISOQUINOLINE; 1,2 DIMETHYL 5,6 DIHYDROXY 1,2,3,4 TETRAHYDROISOQUINOLINE; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 2 METHYL 6,7 DIHYDROXY 1,2,3,4 TETRAHYDROISOQUINOLINE; ALKANE DERIVATIVE; BENSERAZIDE; BENSERAZIDE PLUS LEVODOPA; BETA CARBOLINE DERIVATIVE; CARBIDOPA; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; CYANIDE; DIELDRIN; DOPAMINE; HEAVY METAL; HEPTACHLOR; HYDROXYL RADICAL; ISOQUINOLINE DERIVATIVE; LEVODOPA; N METHYLSALSOLINOL; NEUROTOXIN; ORGANOPHOSPHATE PESTICIDE; OXIDOPAMINE; PESTICIDE; PYRIDINE DERIVATIVE; QUINOLINIC ACID; RETICULINE; TETRAHYDROISOQUINOLINE; TOLCAPONE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANGINA PECTORIS; ANXIETY; CHEMOTHERAPY INDUCED EMESIS; DEPRESSION; DISEASE ASSOCIATION; DISEASE COURSE; DOPAMINE METABOLISM; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG METABOLISM; DYSKINESIA; EXCITATION; HALLUCINATION; HEART ARRHYTHMIA; HUMAN; NAUSEA; NERVE CELL; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; REVIEW; SIDE EFFECT; SUBSTANTIA NIGRA;

EID: 33645839280     PISSN: 0091150X     EISSN: 15739031     Source Type: Journal    
DOI: 10.1007/s11094-006-0001-2     Document Type: Review

References (171)

1. B. V. Manyam, Mov. Disord., 5(1), 47-48 (1990).
2. B. V. Manyam and J. R. Sanchez-Ramos, Adv Neurol., 80, 565-574 (1999).
3. J. W. Langston, Neurotoxicology, 23(4-5), 443-450 (2002).
4. E. I. Gusev and A. B. Gekht, Cons. Med., 2(2), 67-70 (2000).
5. B. S. Shastry, Neurosci. Res., 41(1), 5-12 (2001).
6. O. S. Levin, N. V. Fedorova, and I. G. Smolentseva, Ross. Med. Zh., 8(15), 643-647 (2000).
7. H. Rajputa and S. Birdia, Parkinsonism Relat. Disord., 3(4), 175-186 (1997).
8. M. Drobni and E. Kura, Brain Res. Bull., 53(4), 425-430 (2000).
9. M. A. Collins and E. J. Neafsey, Neurotoxicol. Teratol., 24(5), 571-577 (2002).
10. D.A. Di Monte, M. Lavasani, and A. B. Manning-Bog, Neurotoxicology, 23(4-5), 487-502 (2002).
11. J. C. Stoof, A. Winogrodzka, F. L. van Muiswinkel, et al., Eur. J. Pharmacol., 375(1-3), 75-86 (1999).
12. O. Caspi and C. Thomson, Integr. Med., 2(1), 37-42 (1999).
13. J. Najib, Clin. Ther., 23(6), 802-832 (2001).
14. V. K. Kamenetskii, Parkinsonism [in Russian], Piter, St. Petersburg (2001).
15. M. Quik and J.M. Kulak, Neurotoxicology, 23(4-5), 581-594 (2002).
16. M. Quik and G. Jeyarasasingam, Eur. J. Pharmacol., 393(1-3), 223-230 (2000).
17. S. Bharath, M. Hsu, D. Kaur, et al., Biochem. Pharmacol., 64(5-6), 1037-1048 (2002).
18. D. A. Di Monte, Clin. Neurosci. Res., 1(6), 419-426 (2001).
19. J. J. Hagan, D. N. Middlemiss, P. C. Sharpe, et al., Trends Pharmacol. Sci., 18(5), 156-163 (1997).
20. T. Fukuda, Neuropathology., 21(4), 323-332 (2001).
21. D. J. Cordato and D. K. Y. Chan, J. Clin. Neurosci., 11(2), 119-123 (2004).
22. A. Menegon, P. G Board, A. C Blackburn, et al., Lancet., 352(9137), 1344-1346 (1998).
23. G. Bringmann, R. Bruckner, M. Munchbach, et al., Abstracts of Papers. The 4th International Electronic Conference on Synthetic Organic Chemistry (ECSOC-4); www.mdpi.org/ecsoc-4.htm (2000).
24. G. L. Piccinin, M. Piccirilli, G. Finali, et al., Riv. Neurol., 59(3), 103-107 (1989).
25. M. Sandler, J. Willoughby, V. Glover, et al., J. Neural Transm. Suppl., 25, 35-43 (1987).
26. P. Riederer, P. Foley, G. Bringmann, et al., Eur. J. Pharmacol., 442(1-2), 1-16 (2002).
27. P. Jenner, Parkinsonism Relat. Disord., 5(4), 173-177 (1999).
28. P. T. Lansbury and A. Brice, Curr. Opin. Cell Biol., 14(5), 653-660 (2002).
29. A. M. Lozano, A. E. Lang, W. D. Hutchison, et al., Curr. Opin. Neurobiol., 8(6), 783-790 (1998).
30. S. G. Speciale, Neurotoxicol. Teratol., 24(5), 607-620 (2002).
31. D. A. Gearhart, M. A. Collins, J. M. Lee, et al., Neurobiol. Dis., 7(3), 201-211 (2000).
32. R. Soto-Otero, E. Mindez-Ilvarez, R. Riguera-Vega, et al., Brain Res., 802(1-2), 155-162 (1998).
33. G. Bringmann, D. Feineis, R. God, et al., Bioorg. Med. Chem., 10(7), 2207-2214 (2002).
34. R. G. Booth, A. Trevor, T. P. Singer, et al., J. Med. Chem., 32(2), 473-477 (1989).
35. Y. Akao, W. Maruyama, Hong Yi, et al., Neurosci. Lett., 326(2), 105-108 (2002).
36. B. Janetzky, R. God, G. Bringmann, et al., J. Neural Transm. Suppl., 46, 265-273 (1995).
37. R. Soto-Otero, E. Mendez-Alvareza, I. Sanchez-Sellero, et al., Neurosci. Lett., 298(3), 187-190 (2001).
38. A. Moser, J. Scholz, F. Nobbe, et al., J. Neurol. Sci., 131(2), 183-189 (1995).
39. W. Maruyama, T. Abe, H. Tohgi, et al., Neurosci. Lett., 262(1), 13-16 (1999).
40. A. F. Miranda, R. J. Boegman, R. J. Beninger, et al., Neuroscience, 78(4), 967-975 (1997).
41. V. N. Shtok, O. S. Levin, and N. V. Fedorova, Extrapyramidal Disorders: Classification, Terminology, Diagnostics, Treatment [in Russian], Med. Inform. Agency, Moscow (2002).
42. S. Hunot, A. Hartmann, and E. C. Hirsch, Clin. Neurosci. Res., 1(6), 434-443 (2001).
43. Yi He, Wei-Dong Le, and S. H. Appe, Exp. Neurol., 176(2), 322-327 (2002).
44. Y. Itzhak, D. Mash, S. H. Zhang, et al., Mol. Pharmacol., 39(3), 385-393 (1991).
45. S. Parkin, D. Nandi, N. Giladi, et al., Stereotact. Funct. Neurosurg., 77(1-4), 72 (2001).
46. A. Williams and R. Waring, Br. J. Hosp. Med., 49(10), 716-719 (1993).
47. T. Nagatsu, Neurosci. Res., 29(2), 99-111 (1997).
48. J. A. Wilson, T. J. Doyle, and Y. S. Lau, Neurosci. Lett., 108(1-2), 218 (1990).
49. G. T. Liberatore, V. Jackson-Lewis, S. Vukosavic, et al., Nat. Med., 5(12), 1403-1409 (1999).
50. D. A. Kharkevich, Pharmacology [in Russian], GEOTAR Meditsina, Moscow (1999), pp. 202-208.
51. K. W. Lange, P. A. Löoschmann, E. Sofic, et al., Naunyn Schmiedebergs Arch. Pharmacol., 348(6), 586-592 (1993).
52. M. Goulet and B. K. Madras, J. Pharmacol. Exp. Ther., 292(2), 714-724 (2000).
53. E. Grinblatt, S. Mandel, G. Maor, et al., J. Neurochem., 77(1), 146-156 (2001).
54. I. Kurkowska-Jastrzebska, M. Babiuch, I. Joniec, et al., Int. Immunopharmacol., 2(8), 1213-1218 (2002).
55. A. Czlonkowska, M. Kohutnicka, I. Kurkowska-Jastrzebska, et al., Neurodegeneration, 5(2), 137-143 (1996).
56. M. Gerlach, P. Riederer, H. Przuntek, et al., Eur. J. Pharmacol., 208(4), 273-286 (1991).
57. J. A. Wilson, J. S. Wilson, and F. F. Weight, Brain. Res., 425(2), 376-379 (1987).
58. I. J. Kopin and S. P. Markey, Annu. Rev. Neurosci., 11, 81-96 (1988).
59. Y. Hirata, H. Sugimura, H. Takei, et al., Brain. Res., 397(2), 341-344 (1986).
60. K. F. Tipton, J. M. McCrodden, and M. B. Youdim, Biochem. J., 240(2), 379-383 (1986).
61. Y. Singh, R. Bhatnagar, G. S. Sidhu, et al., Arch. Biochem. Biophys., 271(1), 217-222 (1989).
62. E.-S. Y. Lee and C. G. Charlton, Pharmacol. Biochem. Behav., 70(1), 105-114 (2001).
63. O. M. Adeyemo, M. B. Youdim, S. P. Markey, et al., Eur. J. Pharmacol., 240(2-3), 185-193 (1993).
64. B. G. Gold and J. G. Nutt, Curr. Opin. Pharmacol., 2(1), 82-86 (2002).
65. J. N. Chacon and T. G. Truscott, J. Photochem. Photobiol. B, 11(3-4), 261-267 (1991).
66. T. D. Buckman, R. Chang, M. S. Sutphin, et al., Biochem. Biophys. Res. Commun., 151(2), 897-904 (1988).
67. M. Sedelis, K. Hofele, G. W. Auburger, et al., Behav. Genet., 30(3), 171-182 (2000).
68. R. A. Sadekov and A. M. Vein, Therapy of Parkinsonism [in Russian], Med. Inform. Agency, Moscow (2001), pp. 11-57.
69. M. A. Collins., Parkinsonism Relat. Disord., 8(6), 417-422 (2002).
70. H. Mochizuki, H. Hayakawa, M. Migita, et al., Proc. Natl. Acad. Sci. USA, 98(19), 10918-10923 (2001).
71. R. F. Villa, R. Arnaboldi, B. Ghigini, et al., Neurochem. Res., 17(11), 1147-1154 (1992).
72. A. Mouatt-Prigent, J. O. Karlsson, Y. Agid, et al., Neuroscience, 73(4), 979-987 (1996).
73. Taotao Wei, Chang Chen, Jingwu Hou, et al., Biochim. Biophys. Acta: Mol. Cell Res., 1498(1), 72-79 (2000).
74. Y. Muramatsu, R. Kurosaki, T. Mikami, et al., Metab. Brain Dis., 17(3), 169-182 (2002).
75. C. Pifl, G. Schingnitz, and O. Hornykiewicz, Neuroscience, 44(3), 591-605 (1991).
76. H. Przuntek, H. Russ, K. Henning, et al., Life Sci., 37(13), 1195-1200 (1985).
77. O. Pastoris, M. Dossena, P. Foppa, et al., Pharmacol. Res., 31(6), 361-369 (1995).
78. K. Matsubaru, T. Senda, T. Uezono, et al., Neurosci. Lett., 302(2-3), 65-68 (2001).
79. Z. Hauptman, J. Grefe, and H. Remane, Organic Chemistry [Russian translation], Khimiya, Moscow (1979).
80. A. Pinna, C. Corsi, A. R. Carta, et al., Eur. J. Pharmacol., 446(1-3), 75-82 (2002).
81. Xue-Xiang Zhang, Zi-Tao Zhu, and Guo-Zhang Jin, Life Sci., 63(7), 537-544 (1998).
82. D. S. Bhakuni, S. Gupta, and S. Jain, Tetrahedron, 39(23), 4003-4010 (1983).
83. T. Yamakawa and S. Ohta, Neurosci. Lett., 259(3), 157-160 (1999).
84. M. Gerlach, Ai-Ying Xiao, C. Heim, et al., Neurosci. Lett., 257(1), 17-20 (1998).
85. L. Jost, N. Beuscher, T. Zimmermann, et al., Arzneim. Forsch., 48(1), 1-5 (1998).
86. Neurotoxic Factors in Parkinson's Disease and Related Disorders, M. A. Collins, E. J. Neafsey, in: A. Storch, M. A. Collins (eds.), Kluwer-Plenum Publishers, New-York, (2001), pp. 115-130.
87. K. Matsubara, T. Senda, T. Uezono, et al., Eur. J. Pharmacol., 348(1), 77-84 (1998).
88. D. A. Gearhart, E. J. Neafsey, and M. A. Collins, Neurochem. Int., 40(7), 611-620 (2000).
89. D. A. Gearhart, E. J. Neafsey, and M. A. Collins, Neurochem. Res., 22(2), 113-121 (1997).
90. G. Bringmann, D. Feineis, R. Bruckner, et al., Bioorg. Med. Chem., 8(6), 1467-1478 (2000).
91. G. Bringmann, M. Munchbach, D. Feineis, et al., Neurosci. Lett., 304(1-2), 41-44 (2001).
92. V. G. Bashkatova, Proceedings of the 6th Int. Conf. quot;Bioantioxidant" [in Russian], Moscow (2002), pp. 62-63.
93. V. Z. Lankin, Proceedings of the 6th Int. Conf. "Bioantioxidant" [in Russian], Moscow (2002), pp. 341-343.
94. M. Ebadi, S. K. Srinivasan, and M. D. Baxi, Prog. Neurobiol., 48(1), 1-19 (1996).
95. S. P. Thong and F. Watt, Nucl. Instrum. Methods Phys. Res. B, 158(1-4), 741-749 (1999).
96. J. A. Temlett, J. P. Landsberg, F. Watt, et al., J. Neurochem., 62(1), 143-146 (1994).
97. B. T. Chen, M. V. Avshalumov, et al., J. Neurophysiol., 87(2), 1155-1158 (2002).
98. J. N. Joyce, H. L. Ryoo, T. B. Beach, et al., Brain Res., 955, 138-152 (2002).
99. B. Drukarch and F. L. van Muiswinkel, Biochem. Pharmacol., 59(9), 1023-1031 (2000).
100. L. Zou, J. Jankovic, D. B. Rowea, et al., Life Sci., 64(15), 1275-1285 (1999).
101. J. S. K. Han and A. Y. Sun, Free Radical Biol. Med., 25(4-5), 512-518 (1998).
102. C. A. Colton, F. Pagan, J. Snell, et al., Exp. Neurol., 132(1), 54-61 (1995).
103. G. Di Chiara, M. Morelli, E. Acquaset, et al., Arzneim. Forsch., 42(22), 231-237 (1992).
104. M. D. Mashkovskii, Khim.-Farm. Zh., 10(7), 3-11 (1976).
105. C. Missale, S. R. Nash, S. W. Robinson, et al., Physiol. Rev., 78(1), 189-225 (1998).
106. G. Emilien, J.-M. Maloteaux, M. Geurts, et al., Pharmacol. Ther., 84(2), 133-156 (1999).
107. G. Klopman and A. Sedykh, BMC Pharmacol. 2, 8 (2002); http://www.biomedcentral.com/1471-2210/2/8.
108. Histology (Introduction to Pathology) [in Russian], É. G. Ulumbekov and Yu. A. Chelyshev (eds.), GEOTAR Meditsina, Moscow (1997).
109. G. L. Patrick, An Introduction to Medicinal Chemistry, Oxford University Press, New York (2001).
110. A. Lledo, Parkinsonism Relat. Disord., 7(1), 51-58 (2000).
111. A. Haapalinn and I.-B. Linden, J. Neurol Sci., 150(1), S262 (1997).
112. T. Nakazato and A. Akiyama, Brain Res., 930(1-2), 134-142(2002).
113. V. N. Shtok and N. V. Fedorova, Rus. Med. Zh., 6(13), 4-10 (1998).
114. R. G. Boroyan, Clinical Pharmacology: Psychiatry, Neurology, Endocrinology, Rheumatology [in Russian], Med. Inform. Agency, Moscow (2000), pp. 117-141.
115. E. A. Shirokov, Rus. Med. Zh., 9(7-8), 328-330 (2001).
116. R. J. Carey, Huiliang Dai, M. Pinheiro-Carrera, et al., Biol. Psychiatry, 38(10), 669-676 (1995).
117. B. Henry, S. H. Fox, A. R. Crossman, et al., Exp. Neurol., 171(1), 139-146 (2001).
118. G. J. Fici, H. Wu, P. F. Von Voigtlander, et al., Life Sci., 60(18), 1597-1603 (1997).
119. J. D. Oh, P. Del Dotto, and T. N. Chase, Neurosci. Lett., 228(1), 5-8 (1997).
120. V. Bonifati and G. Meco, Pharmacol. Ther., 81(1), 1-36 (1999).
121. J.-L. Moreau, M. Fava, F. Jenck, et al., Biol. Psychiatry, 42(1), 40S (1997).
122. J. Leppaenen, E. Wegelius, T. Nevalainen, et al., J. Mol. Struct., 562(1-3), 129-136 (2001).
123. D. A. Learmonth, M. A. Vieira-Coelho, J. Benes, et al., J. Med. Chem., 45(3), 685-695 (2002).
124. W. G. Ondo, C. Hunter, K. D. Vuong, et al., Parkinsonism Relat. Disord., 6(4), 237-240 (2000).
125. E. Nissinen, P. Kaheinen, K. E. Penttila, et al., Eur. J. Pharmacol., 340(2-3), 287-294 (1997).
126. P. Lautala, M. Kivimaa, H. Salomies, et al., Pharm. Res., 14(10), 1444-1448 (1997).
127. A. Parada, A. I. Loureiro, M. A. Vieira-Coelho, et al., Eur. J. Pharmacol., 420(1), 27-32 (2001).
128. M. Yamada and H. Yasuhara, Neurotoxicology, 85(1-2), 215-221 (2004).
129. M. Strolin Benedetti and P. Dostert, J. Neural. Transm. Suppl., 23, 103-119 (1987).
130. J. Vetulani, Eur. Neuropsychopharmacol., 6(1), S1 (1996).
131. V. Perez and M. Unzet, Neurochem. Int., 42(3), 221-229 (2003).
132. R. W. Fuller, S. K. Hemrick-Luecke, and K. W. Perry, J. Pharmacol. Exp. Ther., 247(2), 531-535 (1988).
133. B. Cutillas, S. Ambrosio, and M. Unzet, Neurosci. Lett., 329(2), 165-168 (2002).
134. M. B. Youdim and M. Weinstock, Cell. Mol. Neurobiol., 21(6), 555-573 (2001).
135. J. M. Rabey, I. Sagi, M. Huberman, et al., Clin. Neuropharmacol., 23(6), 324-330 (2000).
136. A. Kupsch, Curr. Opin. Investig. Drugs., 3(5), 794-797 (2002).
137. P. Riederer and M. B. Youdim, J. Neurochem., 46(5), 1359-1365 (1986).
138. A. Kalir, A. Sabbagh, and M. B. Youdim, Br. J. Pharmacol., 73(1), 55-64 (1981).
139. Z. Speiser, R. Levy, and S. Cohen, J. Neural. Transm. Suppl., 52, 287-300 (1998).
140. J. P. Finberg and M. B. Youdim, Br. J. Pharmacol., 85(2), 541-546 (1985).
141. J. Wouters, F. Ooms, S. Jegham, et al., J. Med. Chem., 32(9), 721-730 (1997).
142. F. Ooms, R. Frédérick, F. Durant, et al., Bioorg. Med. Chem. Lett., 13(1), 69-73 (2003).
143. F. Mann, F. Chimenti, A. Bolasco, et al., Bioorg. Med. Chem. Lett., 12(24), 3629-3633 (2002).
144. L. Lebreton, O. Curet, S. Gueddari, et al., J. Med. Chem., 38(24), 4786-4792 (1995).
145. J. Matsumoto, T. Takahashi, M. Agata, et al., Jpn. J. Pharmacol., 65(1), 51-57 (1994).
146. Ch. Z. Ding and R. B. Silverman, J. Med. Chem., 36(23), 3606-3610 (1993).
147. Y. Ohmomo, K. Murakami, M. Hirata, et al., Chem. Pharm. Bull., 40(7), 1789-1792 (1992).
148. H. Rafii, S. Chalon, J.-E. Ombetta, et al., Nucl. Med. Biol., 22(5), 617-623 (1995).
149. L. D. Snell, J. Glanz, and B. Tabakoff, Alcohol Clin. Exp. Res., 26(7), 1105-1113 (2002).
150. S. Henriot, C. Kuhn, R. Kettler, et al., J. Neural. Transm. Suppl., 41, 321-325 (1994).
151. Ch. Z. Ding and R. B. Silverman, Bioorg. Med. Chem. Lett., 3(10), 2077-2078 (1993).
152. M. G. Palfreyman, I. A. McDonald, P. Bey, et al., Prog. Neuropsychopharmacol. Biol. Psychiatry, 12(6), 967-987 (1988).
153. M. V. Kindt and R. E. Heikkila, Life Sci., 38(16), 1459-1462 (1986).
154. J. R. Fozard, M. G. Palfreyman, M. Robin, et al., Br. J. Pharmacol., 87(1), 257-264 (1986).
155. S. Rose, M. Nomoto, E. A. Jackson, et al., Neuropharmacology, 28(11), 1211-1216 (1989).
156. J. E. Sprague and D. E. Nichols, Psychopharmacology (Berlin)., 118(3), 357-359 (1995).
157. K. T. Finnegan, Mov. Disord., 8(1), S14-S19 (1993).
158. A. Clow, C. Freestone, E. Lewis, et al., Neurosci. Lett, 164(1-2), 41-43 (1993).
159. S. Kutt, A. Kalgutkar, and N. Castagnoli, Chem. Res. Toxicol., 7(6), 740-744 (1994).
160. L. Hall, S. Murray, K. Castagnoli, et al., Chem. Res. Toxicol., 5(5), 625-633 (1992).
161. A. Carotti, A. Carrieri, S. Chimichi, et al., Bioorg. Med. Chem. Lett., 12(24), 3551-3555 (2002).
162. M. Minami, N. Hamaue, T. Endo, et al., Nippon Yakurigaku Zasshi., 114(1), 186-191 (1999).
163. V. Glover, A. Medvedev, and M. Sandler, Life Sci., 57(22), 2073-2079 (1995).
164. E. A. Budygin, R. R. Gainetdinov, M. R. Kilpatrick, et al., Eur. J. Pharmacol., 370(2), 125-131 (1999).
165. R. B. Rothman and J. R. Glowa, Mol. Neurobiol., 11(1-3), 1-19 (1995).
166. U. Sogaard, J. Michalow, B. Butler, et al., Int. Clin. Psychopharmacol., 5(4), 237-251 (1990).
167. H. Tsukada, N. Harada, S. Nishiyama, et al., Brain Res., 860(1-2), 141-148 (2000).
168. C. W. Schindler and G. N. Carmona, Pharmacol. Biochem. Behav., 72(4), 857-863 (2002).
169. M. D. Mashkovskii, Drugs [in Russian], Novaya Volna, Moscow (2000), Vol. 1.
170. G. G. Trib, Ch. Woumber, V. Schoumnborn, et al., Exp. Gerontol., 36(10), 1761-1771 (2001).
171. A. S. Kadykov, Zh. Nevropatol. Psikhiatr., 76, 174-178 (1976).